In Brief: Ostex/SmithKline Beecham Clinical Labs
This article was originally published in The Gray Sheet
Ostex/SmithKline Beecham Clinical Labs: Firms enter agreement under which SmithKline will market Ostex' Osteomark test, approved for use in the U.S. and overseas to measure human bone resorption. SmithKline has a sales force of 400 and operates 17 regional laboratories in the U.S. Ostex, which has a direct sales force of 14, says the agreement with SmithKline complements existing pacts with Corning Metpath and Corning Nichols Institute for U.S. marketing and sales of the urine-based assay...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.